繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-830、SNP-840

SNP-830、SNP-840

Indication
Hepatotoxicity-free Analgesic
Product Advantages
1. Hepatotoxicity-free Acetaminophen prescription Combo
2. A new combination with great safety margin
Status
After the approval of SNP-810 Plan a clinical trial with / without bioequivalent study for NDA
Competitive Edge
1. No hepatotoxicity-free acetaminophen prescription Combo on the market
2. Acetaminophen prescription combos were requested by USFDA to reduce the dose to below 325 mg ( potency affected )
3. Remove or modify the FDA liver warning
4. Regain the AAP dose to 500 mg or more
5. Grab the market of other pain controllers
6. The two choose one license
Potential Market
Acetaminophen prescription Combo sales are 2.7 billion USD a year (US only)


好玩棋牌 云南时时彩玩法说明 内蒙古11选五内蒙古11 上海十一选五一定牛 北京11选5玩法 好彩1+1好彩1+1 山西体彩十一选五规则 11选最强规律 北京福彩快乐8怎么玩 江西快3开奖走势图结果 在线配资